Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07765303

Skin Type Determination Using Image Artificial Intelligence

Skin color, how easily a person burns or tans in the sun (skin phototype), and the amount of chronic sun damage in the skin are important factors in skin health. These characteristics influence a person's risk of skin cancer, how skin diseases appear, how well treatments work, and how accurately doctors and artificial intelligence (AI) systems can diagnose skin conditions. However, current methods for classifying these characteristics are often imprecise and rely heavily on subjective assessments. As a result, both healthcare professionals and patients may incorrectly classify skin type, which can lead to inaccurate risk assessments and less personalized care.

This study aims to develop and validate AI algorithms that can accurately classify skin pigmentation, skin phototype, and accumulated sun damage using photographs of the skin. Unlike existing approaches, the study combines several different methods to create a more objective "ground truth" for training the AI. These methods include skin color measurements using spectrophotometry or colorimetry, assessments using the Monk Skin Tone Scale, questionnaires about sun sensitivity, and clinical evaluations by trained observers. By combining these data sources, the researchers hope to create a more reliable and scientifically robust classification system.

The study will recruit adults aged 18 years and older from several countries, including countries from all continents. Participants will complete a questionnaire about their skin, propensity to burn and sun exposure history. Researchers will then take standardized close-up and dermoscopic images of the skin on the arm and forearm, measure skin pigmentation using objective instruments when available, and assess skin phototype and sun damage. No invasive procedures will be performed, and no personally identifiable information will be collected.

The collected images and measurements will be used to train deep learning AI models. The researchers aim to develop algorithms that can classify skin pigmentation with at least 85% accuracy, skin phototype with at least 75% accuracy, and sun damage with at least 80% accuracy compared with the combined reference assessments. The algorithms will then be tested in independent datasets, including large dermatology image databases from Sweden, to evaluate how well they perform in different populations.

The study has several potential benefits. More accurate classification of skin characteristics could improve personalized skin cancer risk assessments and allow prevention advice to be tailored to individual needs. This may help identify people who would benefit from closer surveillance and stronger sun protection recommendations while avoiding unnecessary restrictions for people at lower risk. Improved classification could also enhance the diagnosis and management of inflammatory skin diseases and skin cancers, which can appear differently in people with different skin tones.

An additional goal is to address known biases in dermatology AI systems, which often perform less accurately in individuals with darker skin. By including participants with a wide range of skin tones and backgrounds, the researchers aim to contribute to the benchmarking of AI-driven medical devices wich hopefully can result in the development of fairer and more equitable AI tools.

The study involves minimal risk. Only photographs of the arm and forearm will be taken, and researchers will avoid capturing tattoos, prominent scars, or other identifying features. All data will be stored securely and only accessible to authorized researchers. The potential benefits of improving skin disease diagnosis, skin cancer prevention, and fairness in medical AI are considered to outweigh the small privacy risks associated with participation.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil

Loading trial locations.

About this study

Skin pigmentation, skin phototype, and photodamage are important determinants of skin cancer risk, dermatological disease presentation, treatment response, and prognosis. They also influence the performance of artificial intelligence (AI) systems developed for dermatological diagnosis and decision support. Despite their clinical importance, these characteristics are commonly assessed using subjective classification systems with limited accuracy and reproducibility. Misclassification occurs both in self-reported and clinician-reported assessments, which may reduce the precision of individualized risk assessments, prevention strategies, and clinical decision-making.

Current classification methods often rely on the Fitzpatrick skin phototype scale and visual assessment of skin pigmentation and photodamage. Although widely used, these approaches have recognized limitations, particularly across diverse populations and skin tones. Objective measurement techniques, such as reflectance spectrophotometry and colorimetry, provide more accurate assessments of skin pigmentation but are not routinely available in clinical practice and do not directly measure phototype or accumulated photodamage. Consequently, there is a need for more robust, scalable, and objective methods to characterize skin pigmentation, phototype, and photodamage.

Recent advances in deep learning have demonstrated high performance in image-based medical applications, including dermatology. However, most dermatological AI systems have focused on lesion detection and classification, while AI-based assessment of fundamental skin characteristics remains underdeveloped. Furthermore, many existing AI systems have been trained on datasets lacking detailed and reliable information on skin pigmentation, phototype, and photodamage, limiting their generalizability and raising concerns regarding fairness and performance across different skin types.

This international multicenter observational study aims to develop and validate deep learning algorithms capable of classifying skin pigmentation, skin phototype, and photodamage from clinical and dermoscopic skin images. The study will recruit adult participants from multiple countries representing a broad spectrum of skin pigmentation levels, phototypes, and sun exposure patterns.

Participants will complete standardized questionnaires, including the Fitzpatrick skin phototype questionnaire and questions related to sun exposure and skin characteristics. Clinical and dermoscopic images will be obtained from predefined anatomical sites on the upper arm and forearm. Skin pigmentation will be assessed using objective measurement methods, including colorimetry and/or spectrophotometry where available, as well as visual classification using the Monk Skin Tone Scale. Trained study personnel will additionally assess Fitzpatrick skin phototype and the degree of photodamage using established clinical scales.

Data collected from questionnaires, objective measurements, visual assessments, and imaging will be combined to create reference standards for skin pigmentation, phototype, and photodamage. Deep learning models will subsequently be developed using the collected clinical and dermoscopic images. Model performance will be evaluated against the reference standards using measures of diagnostic accuracy, including sensitivity, specificity, accuracy, and area under the receiver operating characteristic curve.

The study will also investigate the agreement between patient-reported assessments, clinician assessments, objective pigmentation measurements, and AI-derived classifications. In addition, external validation studies will be performed using independent dermatological image datasets to assess model robustness and generalizability across different populations, geographic regions, and imaging systems.

The anticipated outcome of the study is the development of validated AI algorithms capable of providing standardized and objective assessments of skin pigmentation, phototype, and photodamage. Such tools may support future research, improve characterization of dermatological datasets, facilitate evaluation of AI fairness across skin types, and contribute to more personalized approaches to skin cancer prevention, risk stratification, and dermatological care.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Aged 18 years or older
  • Able and willing to provide informed consent (oral or written, according to local regulations)
  • Willing to complete the study questionnaire
  • Willing to undergo non-invasive skin imaging and skin characteristic assessments of predefined sites on the upper arm and forearm

Exclusion criteria

  • Younger than 18 years of age
  • Unable to provide informed consent
  • Unable to complete study procedures
  • Tattoos, prominent scars, wounds, skin lesions, dressings, or other identifiable features at the predefined imaging sites that may interfere with image acquisition, assessment quality, or participant anonymity

Treatment and study plan

Skin imaging and skin characteristic assessment

Other

Participants undergo standardized clinical and dermoscopic skin imaging, skin pigmentation measurements, skin phototype assessments, photodamage assessments, and completion of questionnaires. Data are collected for the development and validation of artificial intelligence algorithms for classification of skin pigmentation, phototype, and photodamage.

Primary outcomes

  1. Agreement between AI-derived skin pigmentation (tone) classification and objective skin pigmentation measured by colorimetry/ spectrophotometry (Individual Typology Angle, ITA)

    Time frame: At completion of model development and testing (approximately 2029).

    Skin pigmentation will be measured objectively using spectrophotometry/ colorimetry and summarized as the Individual Typology Angle (ITA). AI-derived skin pigmentation classification will be compared with ITA values using correlation and agreement analyses. ITA is considered the primary reference standard for objective assessment of skin pigmentation in the interpretation of AI performance.

  2. Accuracy of AI-based skin phototype classification

    Time frame: At completion of model development and testing (approximately 2029).

    Accuracy of the deep learning algorithm in classifying skin phototype from clinical and dermoscopic images compared with the reference standard based on the validated Fitzpatrick skin phototype assessment (consisting of 6 categories).

  3. Agreement between AI-derived skin pigmentation (tone) classification and clinician-assessed Monk Skin Tone Scale category

    Time frame: At completion of model development and testing (approximately 2029).

    Skin pigmentation will be assessed visually by trained investigators using the Monk Skin Tone Scale (categories 1 (fair) to 10 (dark)). AI-derived classifications will be compared with clinician-assigned Monk categories using agreement and correlation analyses. The Monk Skin Tone Scale represents the principal visual reference standard for skin tone classification.

  4. Agreement between AI-derived photodamage classification and the Clinical Photonumeric Scale for Photodamage Assessment

    Time frame: At completion of model development and testing (approximately 2029).

    Photodamage will be assessed using the validated Clinical Photonumeric Scale (0-3 for 3 defined pigmentation categories) for Photodamage Assessment. AI-derived photodamage classifications will be compared with the photonumeric scale scores using agreement and correlation analyses. This outcome evaluates the agreement between AI-derived classifications and a validated photonumeric clinical assessment of photodamage.

Secondary outcomes

  1. Agreement between AI-derived facial photodamage classification and the Glogau Photoaging Scale

    Time frame: At completion of model development and testing (approximately 2029).

    Facial photodamage will be assessed by trained investigators using the Glogau Photoaging Scale (1-4). AI-derived photodamage classifications will be compared with Glogau categories using agreement and correlation analyses. The Glogau Photoaging Scale is a widely used clinical grading system for the assessment of facial photoaging.

  2. Agreement between AI-derived skin pigmentation classification and participant self-reported skin tone

    Time frame: At completion of model development and testing (approximately 2029).

    Participants will self-classify their skin tone using the a 5-category skin tone scale for constiutive and facultative skin tone derived from the validated Fitzpatrick skin type questionnaire. Agreement between AI-derived classifications and participant self-reported skin tone will be evaluated using correlation and agreement analyses. This outcome will assess whether AI reflects participants' own perception of their skin tone.

  3. Agreement between AI-derived skin pigmentation classification and observer-reported skin tone

    Time frame: At completion of AI model (approximately 2029)

    Observers will perform a visual assessment of participant complexion and classify participants into one of the 6 Fitzpatrick skin types. Agreement between AI-derived classifications and observer assessments will be evaluated using correlation and agreement analyses. This outcome will determine whether AI performs comparably to routine clinical visual assessment.

  4. Agreement between AI-derived forearm photodamage classification and the Forearm Skin Photoaging Scale

    Time frame: At completion of model development and testing (approximately 2029).

    Photodamage of the dorsal forearm will be assessed by trained investigators using the Forearm Skin Photoaging Scale. This scale is validated and includes assessments of wrinkles (0-4), lentigines (0-4), hypochromias (0-4), actinic keratoses (superficial and hypertrophic, each assessed at a scal 0-4), stellate pseudoscars (0-1), visible veins (0-1), visible purpura (0-1). elastosis (0-2) and loss of elasticity (0-2). AI-derived photodamage classifications will be compared both with the individual measures in the Forearm Skin Photoaging Scale but also to the aggregated score (wrinkle score x9 + lentigines score x4 + actinic keratoses superficial score x4 + actinic keratosis hypertrophic score x1 + visible purpura score x2+ psedoscar score x4 + elastosis score x8 + loss of elasticity score x 16) using agreement and correlation analyses. This outcome evaluates AI performance for assessing chronic sun-induced photodamage of the forearm.

Study contacts

Contact information is provided by the study sponsor or research team.

Anna Asphult, Research nurse

CONTACT

[email protected]

+46 46 172113

Åsa Ingvar, MD PhD

CONTACT

[email protected]

+46 46172243

Sponsors and collaborators

Lead sponsor

Region Skane

Other

Collaborators

  • Erasmus University Rotterdam
  • Hospital Universitario 12 de Octubre
  • Mahidol University
  • Monash University
  • Odense University Hospital
  • Queen Elizabeth Central Hospital, Blantyre, Malawi
  • Sahlgrenska University Hospital
  • The University of Queensland
  • Universidad de los Andes, Chile
  • University of Chile
  • University of Colombo
  • Xiangya Hospital of Central South University

Registry information

Official study title

Skin Pigment Type, Phototype and Photodamage Determination Using Image Analyses Powered by Artificial Intelligence - SPAI Study

Acronym: SPAI

Important dates

Study start
2025
Primary completion
2027
Study completion
2028
First posted
Aug 14, 2026
Registry last updated
Aug 14, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.